Open AccessSuccessful treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis
Author(s) -
Russo Irene,
Miotto Serena,
Colpo Anna,
Marson Piero,
Tison Tiziana,
Ferrazzi Anna,
Alaibac Mauro
Publication year - 2017
Publication title -
international wound journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 63
eISSN - 1742-481X
pISSN - 1742-4801
DOI - 10.1111/iwj.12684
Subject(s) - pyoderma gangrenosum , apheresis , medicine , granulocyte , monocyte , leukapheresis , dermatology , pathology , immunology , platelet , disease , stem cell , biology , cd34 , genetics
Pyoderma gangrenosum is a neutrophilic dermatosis clinically characterised by the presence of painful skin ulcerations with erythematous and undetermined borders and histologically by the presence of neutrophilic infiltrates in the dermis. Granulocyte and monocyte adsorption apheresis, also called granulocytapheresis, is a therapeutic strategy for extracorporeal immunomodulation that selectively removes activated granulocytes and monocytes/macrophages from the peripheral blood. Here, we report a case of a 73‐year‐old patient affected by a severe form of pyoderma gangrenosum presenting with multiple painful ulcers and pustules on his trunk and extremities. The disease was resistant to high doses of methylprednisolone and methotrexate and successfully treated by granulocyte and monocyte adsorption apheresis. To the best of our knowledge, this is the first report on the efficacy of granulocyte and monocyte adsorption apheresis in pyoderma gangrenosum in Europe.